According to a new report, serious gaps exist in the research pipeline regarding the development of prevention and treatment options for sexually transmitted infections such as gonorrhea, chlamydia, and syphilis.
Researchers are investigating a rapid test that not only checks for gonorrhea infection, but also signals if a particular strain is antibiotic-resistant. On another front, scientists report that one dose of a developmental oral antibiotic proves effective in treating uncomplicated genital infections caused by gonorrhea.
Since 2006, the Centers of Disease Control and Prevention has recommended the use of expedited partner therapy (EPT) for treatment of sexually transmitted infections such as gonorrhea and chlamydia, but the infection rate continues to climb.
2.3 million cases of chlamydia, gonorrhea, and syphilis were reported in 2017
October 25, 2018
Nearly 2.3 million cases of chlamydia, gonorrhea, and syphilis were diagnosed in the United States in 2017, preliminary data indicate. This number surpasses the previous high level in 2016 and marks the fourth consecutive year of sharp increases in sexually transmitted infections.
This article reviews the current status of expedited partner therapy (EPT), which involves treating the heterosexual partners of patients diagnosed with chlamydia or gonorrhea by providing the medication or a prescription for the patient to give to the partner without a healthcare provider first examining the partner.
In a recently released study, Centers for Disease Control and Prevention (CDC) researchers report that while 81% of patients diagnosed with gonorrhea were treated using dual therapy, nearly one in five were treated with a different regimen.
More than 2 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2016, the highest number ever. Most of the new diagnoses were attributed to chlamydia (about 1.6 million), with 470,000 cases of gonorrhea and almost 28,000 cases of primary and secondary syphilis.
More than 2 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2016, the highest number ever, according to the latest surveillance from the Centers for Disease Control and Prevention.
About 820,000 new gonococcal infections occur in the United States each year, with some 570,000 appearing in young people ages 15-24. In an effort to stem the tide of infection, science has identified a potential new treatment, which uses a peptide to disrupt an enzyme the microbe needs to respirate.